1. Home
  2. MIRM vs CNXC Comparison

MIRM vs CNXC Comparison

Compare MIRM & CNXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • CNXC
  • Stock Information
  • Founded
  • MIRM 2018
  • CNXC 1991
  • Country
  • MIRM United States
  • CNXC United States
  • Employees
  • MIRM N/A
  • CNXC N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • CNXC Computer Software: Prepackaged Software
  • Sector
  • MIRM Health Care
  • CNXC Technology
  • Exchange
  • MIRM Nasdaq
  • CNXC Nasdaq
  • Market Cap
  • MIRM 3.3B
  • CNXC 3.3B
  • IPO Year
  • MIRM 2019
  • CNXC N/A
  • Fundamental
  • Price
  • MIRM $73.14
  • CNXC $55.49
  • Analyst Decision
  • MIRM Strong Buy
  • CNXC Buy
  • Analyst Count
  • MIRM 10
  • CNXC 4
  • Target Price
  • MIRM $74.20
  • CNXC $68.75
  • AVG Volume (30 Days)
  • MIRM 679.0K
  • CNXC 636.9K
  • Earning Date
  • MIRM 11-11-2025
  • CNXC 09-25-2025
  • Dividend Yield
  • MIRM N/A
  • CNXC 2.40%
  • EPS Growth
  • MIRM N/A
  • CNXC N/A
  • EPS
  • MIRM N/A
  • CNXC 3.65
  • Revenue
  • MIRM $429,161,000.00
  • CNXC $9,625,029,000.00
  • Revenue This Year
  • MIRM $53.08
  • CNXC $3.62
  • Revenue Next Year
  • MIRM $20.45
  • CNXC $3.16
  • P/E Ratio
  • MIRM N/A
  • CNXC $15.22
  • Revenue Growth
  • MIRM 62.33
  • CNXC 11.31
  • 52 Week Low
  • MIRM $36.86
  • CNXC $36.28
  • 52 Week High
  • MIRM $78.10
  • CNXC $66.49
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 58.57
  • CNXC 60.64
  • Support Level
  • MIRM $73.35
  • CNXC $52.93
  • Resistance Level
  • MIRM $74.99
  • CNXC $54.02
  • Average True Range (ATR)
  • MIRM 2.37
  • CNXC 2.01
  • MACD
  • MIRM -0.94
  • CNXC 0.46
  • Stochastic Oscillator
  • MIRM 20.40
  • CNXC 73.46

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About CNXC Concentrix Corporation

Concentrix Corp is a technology enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Frances and Others. Maximum revenue is from Technology and consumer electronics industry and geographically from Philippines.

Share on Social Networks: